OTCMKTS:NEVPF Abliva AB (publ) (NEVPF) Stock Forecast, Price & News Add Compare Share Share Today's Range N/A50-Day Range$0.01▼$0.0152-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsHeadlinesShort InterestProfileChartCompetitorsHeadlinesShort Interest About Abliva AB (publ) (OTCMKTS:NEVPF) StockAbliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.Read More NEVPF Stock News HeadlinesOctober 3, 2023 | investing.comInterfox Resources publ AB (IFOX)October 14, 2022 | investing.comCell Impact publ AB (CELLI)October 4, 2023 | Legacy Research (Ad)Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”January 20, 2022 | nasdaq.comAbliva AB (publ) (NEVPF)November 28, 2020 | finanznachrichten.deBioInvent strengthens Investor RelationsJune 28, 2020 | finance.yahoo.comVenture Fund Manager Has $100 Million for Startups Run by WomenApril 7, 2020 | finance.yahoo.comHere's Why NeuroVive Pharmaceutical (STO:NVP) Must Use Its Cash WiselyFebruary 19, 2020 | seekingalpha.comNeuroVive Pharmaceutical AB reports Q4 resultsOctober 4, 2023 | Behind the Markets (Ad)BREAKING: The truth about war with ChinaForeign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.February 4, 2020 | finance.yahoo.comInvestors Who Bought NeuroVive Pharmaceutical (STO:NVP) Shares Five Years Ago Are Now Down 98%December 20, 2019 | markets.businessinsider.comNeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b StudyDecember 16, 2019 | seekingalpha.comNeuroVive settles dispute with CicloMulsion AGDecember 16, 2019 | finance.yahoo.comNeuroVive Announces Settlement in Dispute With CicloMulsion AGDecember 4, 2019 | ca.finance.yahoo.comHow Much Did NeuroVive Pharmaceutical AB's (STO:NVP) CEO Pocket Last Year?December 4, 2019 | finance.yahoo.comHow Much Did NeuroVive Pharmaceutical AB's (STO:NVP) CEO Pocket Last Year?October 29, 2019 | finance.yahoo.comHave Insiders Been Buying NeuroVive Pharmaceutical AB (STO:NVP) Shares?September 26, 2019 | finance.yahoo.comWe Think NeuroVive Pharmaceutical (STO:NVP) Needs To Drive Business Growth CarefullyAugust 23, 2019 | finance.yahoo.comHow Does Investing In NeuroVive Pharmaceutical AB (STO:NVP) Impact The Volatility Of Your Portfolio?May 22, 2019 | finance.yahoo.comCatalyst Pharma (CPRX) Rides on Successful Launch of FirdapseMay 21, 2019 | finance.yahoo.comNeuroVive Pharmaceutical AB Interim Report January - March 2019March 25, 2019 | finance.yahoo.comNeuroVive Pharmaceutical AB Publishes 2018 Annual ReportMarch 7, 2019 | finance.yahoo.comNeuroVive Receives SEK 28.2 Million in a Directed New Share IssueFebruary 21, 2019 | finance.yahoo.comNeuroVive Enters Commercial Partnership With Oroboros Instruments on Mitochondrial Medicine Research CompoundsSee More Headlines Receive NEVPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abliva AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address NEVPF Company Calendar Today10/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:NEVPF CUSIPN/A CIKN/A Webwww.neurovive.com Phone(646) 275-6220Fax46-4-688-883-48Employees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$20,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares403,010,000Free FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Ellen K. Donnelly Ph.D. (Age 49)Chief Exec. Officer Ms. Catharina Jz Johansson (Age 56)Deputy CEO, CFO & VP of Investor Relations Dr. Eskil Elmér (Age 53)Chief Scientific Officer & VP of Discovery Daniel SchaleDirector of CommunicationsDr. Magnus Hansson (Age 47)Chief Medical Officer and VP of Preclinical & Clinical Devel. Mr. Dag NesseVP of Clinical OperationsDr. Lars VedinConsultantMore ExecutivesKey CompetitorsAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYAlseres PharmaceuticalsOTCMKTS:ALSEView All Competitors NEVPF Stock - Frequently Asked Questions What is Abliva AB (publ)'s stock symbol? Abliva AB (publ) trades on the OTCMKTS under the ticker symbol "NEVPF." How do I buy shares of Abliva AB (publ)? Shares of NEVPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. How much money does Abliva AB (publ) make? Abliva AB (publ) (OTCMKTS:NEVPF) has a market capitalization of $0.00 and generates $20,000.00 in revenue each year. How can I contact Abliva AB (publ)? Abliva AB (publ)'s mailing address is MEDICON VILLAGE SCHEELEVAGEN 2, LUND V7, 22381. The official website for the company is www.neurovive.com. The company can be reached via phone at (646) 275-6220, via email at ir@abliva.com, or via fax at 46-4-688-883-48. This page (OTCMKTS:NEVPF) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abliva AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.